Warburg Pincus has committed to invest CDN$35 million in Protox, which develops receptor targeted fusion proteins for the treatment of diseases of the prostate and cancer. Warburg is a global PE firm.
PRESS RELEASE
Protox Therapeutics Inc. (the “Company” or “Protox”) (TSX: PRX), a leader in the development of receptor targeted fusion proteins for the treatment of diseases of the prostate and cancer, and Warburg Pincus, a leading global private equity firm, today jointly announced that they have entered into an Investment Agreement.
